418 related articles for article (PubMed ID: 34815389)
1. ACE2-like carboxypeptidase B38-CAP protects from SARS-CoV-2-induced lung injury.
Yamaguchi T; Hoshizaki M; Minato T; Nirasawa S; Asaka MN; Niiyama M; Imai M; Uda A; Chan JF; Takahashi S; An J; Saku A; Nukiwa R; Utsumi D; Kiso M; Yasuhara A; Poon VK; Chan CC; Fujino Y; Motoyama S; Nagata S; Penninger JM; Kamada H; Yuen KY; Kamitani W; Maeda K; Kawaoka Y; Yasutomi Y; Imai Y; Kuba K
Nat Commun; 2021 Nov; 12(1):6791. PubMed ID: 34815389
[TBL] [Abstract][Full Text] [Related]
2. ACE2-like enzyme B38-CAP suppresses abdominal sepsis and severe acute lung injury.
Minato T; Yamaguchi T; Hoshizaki M; Nirasawa S; An J; Takahashi S; Penninger JM; Imai Y; Kuba K
PLoS One; 2022; 17(7):e0270920. PubMed ID: 35867642
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
5. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
[TBL] [Abstract][Full Text] [Related]
6. Structural insights revealed by crystal structure of B38-CAP, an isoenzyme of carboxypeptidase ACE2, the receptor of SARS-CoV-2.
Liu P; Zhang Y; Li Z; Huang J; Wang T; Chen C
Biochem Biophys Res Commun; 2022 May; 606():17-22. PubMed ID: 35338854
[TBL] [Abstract][Full Text] [Related]
7. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
[TBL] [Abstract][Full Text] [Related]
8. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19.
Li K; Meyerholz DK; Bartlett JA; McCray PB
mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553
[TBL] [Abstract][Full Text] [Related]
9. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
Tada T; Fan C; Chen JS; Kaur R; Stapleford KA; Gristick H; Dcosta BM; Wilen CB; Nimigean CM; Landau NR
Cell Rep; 2020 Dec; 33(12):108528. PubMed ID: 33326798
[TBL] [Abstract][Full Text] [Related]
10. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
11. Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein.
Zhang L; Zhang Y; Qin X; Jiang X; Zhang J; Mao L; Jiang Z; Jiang Y; Liu G; Qiu J; Chen C; Qiu F; Zou Z
Crit Care; 2022 Jun; 26(1):171. PubMed ID: 35681221
[TBL] [Abstract][Full Text] [Related]
12. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
13. Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.
Li Z; Peng M; Chen P; Liu C; Hu A; Zhang Y; Peng J; Liu J; Li Y; Li W; Zhu W; Guan D; Zhang Y; Chen H; Li J; Fan D; Huang K; Lin F; Zhang Z; Guo Z; Luo H; He X; Zhu Y; Li L; Huang B; Cai W; Gu L; Lu Y; Deng K; Yan L; Chen S
Cell Metab; 2022 Mar; 34(3):424-440.e7. PubMed ID: 35150639
[TBL] [Abstract][Full Text] [Related]
14. Manipulation of ACE2 expression in COVID-19.
Chaudhry F; Lavandero S; Xie X; Sabharwal B; Zheng YY; Correa A; Narula J; Levy P
Open Heart; 2020 Dec; 7(2):. PubMed ID: 33443121
[TBL] [Abstract][Full Text] [Related]
15. "Molecular Masks" for ACE2 to Effectively and Safely Block SARS-CoV-2 Virus Entry.
Shukla SP; Cho KB; Rustagi V; Gao X; Fu X; Zhang SX; Guo B; Udugamasooriya DG
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445669
[TBL] [Abstract][Full Text] [Related]
16. Multifunctional angiotensin converting enzyme 2, the SARS-CoV-2 entry receptor, and critical appraisal of its role in acute lung injury.
Oz M; Lorke DE
Biomed Pharmacother; 2021 Apr; 136():111193. PubMed ID: 33461019
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility to recombinant SARS-CoV-2 spike protein entry in the lungs of high-fat diet-induced obese mice.
Gotoh K; Satoh F; Uesugi H; Noguchi T; Matsuda N; Sada K; Miyamoto S; Ozeki Y; Yoshida Y; Okamoto M; Masaki T; Kawabe T; Shibata H
FASEB J; 2024 May; 38(10):e23656. PubMed ID: 38752523
[TBL] [Abstract][Full Text] [Related]
18. B38-CAP is a bacteria-derived ACE2-like enzyme that suppresses hypertension and cardiac dysfunction.
Minato T; Nirasawa S; Sato T; Yamaguchi T; Hoshizaki M; Inagaki T; Nakahara K; Yoshihashi T; Ozawa R; Yokota S; Natsui M; Koyota S; Yoshiya T; Yoshizawa-Kumagaye K; Motoyama S; Gotoh T; Nakaoka Y; Penninger JM; Watanabe H; Imai Y; Takahashi S; Kuba K
Nat Commun; 2020 Feb; 11(1):1058. PubMed ID: 32103002
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 receptor binding domain fusion protein efficiently neutralizes virus infection.
Chaouat AE; Achdout H; Kol I; Berhani O; Roi G; Vitner EB; Melamed S; Politi B; Zahavy E; Brizic I; Lenac Rovis T; Alfi O; Wolf D; Jonjic S; Israely T; Mandelboim O
PLoS Pathog; 2021 Dec; 17(12):e1010175. PubMed ID: 34929007
[TBL] [Abstract][Full Text] [Related]
20. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2.
El-Shennawy L; Hoffmann AD; Dashzeveg NK; McAndrews KM; Mehl PJ; Cornish D; Yu Z; Tokars VL; Nicolaescu V; Tomatsidou A; Mao C; Felicelli CJ; Tsai CF; Ostiguin C; Jia Y; Li L; Furlong K; Wysocki J; Luo X; Ruivo CF; Batlle D; Hope TJ; Shen Y; Chae YK; Zhang H; LeBleu VS; Shi T; Swaminathan S; Luo Y; Missiakas D; Randall GC; Demonbreun AR; Ison MG; Kalluri R; Fang D; Liu H
Nat Commun; 2022 Jan; 13(1):405. PubMed ID: 35058437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
